Additional anti-CLDN18.2 CAR-T therapies currently under investigation for the treatment of CLDN18.2-positive G/GEJ cancers are included in Table 3 [105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121]. This evidence concerns the gene CLDN18 and cancer.